← back to search

Molly F. Franke

Harvard University · US
Area of research
Infectious Diseases · Surgery
Research interest
Research interests include Tuberculosis Research and Epidemiology, HIV/AIDS Research and Interventions, Diagnosis and treatment of tuberculosis, and Pneumonia and Respiratory Infections.
h-index
40
citations
5,110
works
225
NIH funding
primary concept
email

Recent publications

Plasma proteomics for biomarker discovery in childhood tuberculosis
Nature Communications 2025cited by 10position: middledoi
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
Clinical Infectious Diseases 2025cited by 4position: middledoi
Conflation of prediction and causality in the TB literature
IJTLD OPEN 2025cited by 1position: middledoi
Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
IJTLD OPEN 2025cited by 1position: lastdoi
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis
PLoS Medicine 2024cited by 13position: middledoi
Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
Nature Communications 2024cited by 9position: lastdoi
The Frequency and Incidence of QT Prolongation With Extended Use of Bedaquiline or Delamanid in a Large, Multi-Country Multidrug-Resistant/Rifampicin-Resistant Tuberculosis Cohort
Clinical Infectious Diseases 2024cited by 7position: middledoi
Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysis
The Lancet Child & Adolescent Health 2023cited by 44position: middledoi
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
American Journal of Respiratory and Critical Care Medicine 2023cited by 18position: lastdoi
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs
Clinical Infectious Diseases 2023cited by 16position: middledoi
Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
The International Journal of Tuberculosis and Lung Disease 2023cited by 13position: middledoi
Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
The International Journal of Tuberculosis and Lung Disease 2023cited by 7position: lastdoi
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up
Clinical Infectious Diseases 2023cited by 7position: lastdoi
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs
Clinical Infectious Diseases 2022cited by 35position: middledoi
Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion
PLoS ONE 2022cited by 6position: lastdoi
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
European Respiratory Journal 2021cited by 16position: middledoi
Seroprevalence of hepatitis B and hepatitis C among blood donors in Sierra Leone: A multi-year retrospective study
International Journal of Infectious Diseases 2020cited by 29position: middledoi
Molecular detection of Mycobacterium tuberculosis from buccal swabs among adult in Peru
Scientific Reports 2020cited by 18position: lastdoi
Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis
PLoS Medicine 2019cited by 133position: middledoi
Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study
BMJ Global Health 2018cited by 98position: middledoi
Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis
Journal of Clinical Microbiology 2016cited by 77position: middledoi
Community-Based Accompaniment Mitigates Predictors of Negative Outcomes for Adults on Antiretroviral Therapy in Rural Rwanda
AIDS and Behavior 2015cited by 23position: middledoi
Concordance of <i>Mycobacterium tuberculosis</i> fluoroquinolone resistance testing: implications for treatment
The International Journal of Tuberculosis and Lung Disease 2015cited by 21position: middledoi
Alcohol, Hospital Discharge, and Socioeconomic Risk Factors for Default from Multidrug Resistant Tuberculosis Treatment in Rural South Africa: A Retrospective Cohort Study
PLoS ONE 2013cited by 79position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Carole D. Mitnick · McGill University Health Centre5 papers (2015–2025)Palwasha Khan · London School of Hygiene & Tropical Medicine4 papers (2022–2025)Karen R. Jacobson · Boston University3 papers (2013–2016)Uzma Khan · McGill University Health Centre3 papers (2022–2025)Helena Huerga · Epicentre (South Africa)3 papers (2022–2025)Mathieu Bastard · Université Claude Bernard Lyon 13 papers (2022–2025)Kwonjune J. Seung · University of Cape Town2 papers (2024–2025) · 2 papers (2024–2025)Megan Murray · Dublin City University2 papers (2013–2016)Annelies W. Mesman · National Institute for Public Health and the Environment2 papers (2020–2020) · 2 papers (2024–2025)Maha Farhat · Harvard University2 papers (2015–2016)Michael Rich · University of Cape Town2 papers (2024–2025) · 2 papers (2022–2025)Róger Calderón · Princeton University2 papers (2020–2025)Heather J. Zar · Medical Research Council1 papers (2025–2025)Megan Murray · University of Kansas1 papers (2015–2015)Francesco Di Gennaro · University of Padua1 papers (2020–2020)Zibiao Zhang · Princeton University1 papers (2020–2020)C. Robert Horsburgh · Boston University1 papers (2022–2022)